Riskpilot← Back to searchSign inGet full accessSCALING LAB AS
ASActiveOrg 928343138Gaustadalléen 21, 0349 OsloBusiness and other management consultancy activities · NACE 7020Est. 20212 employees
Revenue 2024
NOK 2,5M
+166% vs 2023
EBITDA margin
0.1%
-95% vs 2023
Equity ratio
-65.7%
Financial strength
Net profit 2024
NOK -21K
-155% vs 2023
| Revenue | NOK 2,5M | +166% |
| EBITDA | NOK 3K | -95% |
| Net profit | NOK -21K | -155% |
| Total assets | NOK 566K | -35% |
| Equity | NOK -372K | -6% |
| Employees | 2 | — |
Legal name
SCALING LAB AS
Org number
928343138
Legal form
Aksjeselskap
NACE code
7020 · Business and other management consultancy activities
Founded
15. desember 2021
Share capital
NOK 30 000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets medlemmer hver for seg.
Company purpose
Selvstendig eller i samarbeid med andre parter påta seg oppgaver, prosjekter, rådgivningstjenester, konsulentvirksomhet, opplæring og opplæring innen innovasjon, entreprenørskap, forretningsrådgivning, finansiering og oppskalering av selskaper.
Address
Gaustadalléen 21, 0349 Oslo
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 0 | 100 | 930 | 2 477 |
| Staff expenses | −0 | −0 | −566 | −2 075 |
| EBITDA | −110 | −282 | 63 | 3 |
| Depreciation & amort. | −0 | −22 | −25 | −25 |
| EBIT | −110 | −304 | 39 | −22 |
| Net financials | 0 | 0 | 0 | 0 |
| Profit before tax | −110 | −304 | 39 | −21 |
| Tax | −0 | −0 | −0 | −0 |
| Net profit | −110 | −304 | 39 | −21 |
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 265 | 151 | 873 | 566 |
| Equity | −80 | −389 | −350 | −372 |
| Long-term debt | 300 | 540 | 571 | 271 |
| Short-term debt | 45 | 0 | 652 | 666 |
| Total debt | 345 | 540 | 1 223 | 937 |
EBITDA margin
0.1%
This company
15.8%
Market median
-99% vs market
20212024
Equity ratio
-65.7%
This company
38.2%
Market median
-272% vs market
20212024
Return on equity
-2134100.0%
This company
18.4%
Market median
-11598470% vs market
20212024
Net profit margin
-0.9%
This company
8.1%
Market median
-111% vs market
20212024
Asset turnover
4.38×
This company
1.12×
Market median
+291% vs market
20212024
Debt / equity
2.52×
This company
0.62×
Market median
-306% vs market
20212024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
No data on file.
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2026 | — | — | |
| Chairman | 2021 | — | — | |
| Chairman | 2023 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2021 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 70.0% | 70.0% | 2022 | |
Cercis As | Company | 20.0% | 20.0% | 2022 |
World Health Connections As | Company | 10.0% | 10.0% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Framtech Holding As
SCALING LAB AS Board members of SCALING LAB AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Harald Hvidsten | Chairman | 0 companies |
| Werner Hosewinckel Christie | Chairman | 0 companies |
| Per Ingvar Olsen | Chairman | 0 companies |
| Filipa Baltazar Da Costa Vaz | Board of Directors | 0 companies |
| Tom Lindtein | Board of Directors | 0 companies |